Reviewing Protagonist Therapeutics Inc. (PTGX)’s and Nightstar Therapeutics plc (NASDAQ:NITE)’s results

Protagonist Therapeutics Inc. (NASDAQ:PTGX) and Nightstar Therapeutics plc (NASDAQ:NITE) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics Inc. 39.85M 4.36 28.11M -1.30 0.00
Nightstar Therapeutics plc N/A 0.00 42.26M -1.93 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Protagonist Therapeutics Inc. and Nightstar Therapeutics plc.

Profitability

Table 2 shows Protagonist Therapeutics Inc. and Nightstar Therapeutics plc’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics Inc. -70.54% -24.1% -18.8%
Nightstar Therapeutics plc 0.00% -38.7% -35.1%

Liquidity

The Current Ratio and a Quick Ratio of Protagonist Therapeutics Inc. are 6.1 and 6.1. Competitively, Nightstar Therapeutics plc has 7.7 and 7.7 for Current and Quick Ratio. Nightstar Therapeutics plc’s better ability to pay short and long-term obligations than Protagonist Therapeutics Inc.

Institutional & Insider Ownership

Protagonist Therapeutics Inc. and Nightstar Therapeutics plc has shares held by institutional investors as follows: 0% and 49.8%. Protagonist Therapeutics Inc.’s share held by insiders are 1.8%. On the other hand, insiders held about 40.63% of Nightstar Therapeutics plc’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Protagonist Therapeutics Inc. 7.57% -23.09% -20.18% -3.47% -63.94% -66.54%
Nightstar Therapeutics plc -12.92% 23.65% -46.32% -7.57% -23.12% -0.38%

For the past year Nightstar Therapeutics plc has weaker performance than Protagonist Therapeutics Inc.

Summary

On 6 of the 9 factors Protagonist Therapeutics Inc. beats Nightstar Therapeutics plc.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. It primarily focuses on developing oral peptide drugs. The companyÂ’s lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease (IBD); and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD. It is also developing PTG-300, an injectable hepcidin mimetic peptide that is in pre-clinical development stage to treat iron overload disorders, such as b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.